NCT02926690View on ClinicalTrials.gov

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 29, 2017

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Interventions
DRUG

OTS167PO

Single arm, no competitor

Trial Locations (5)

11065

Memorial Sloan Kettering Cancer Center, New York

77030

MD Anderson Cancer Center, Houston

06856

Norwalk Hospital, Norwalk

03756

Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center, Lebanon

New York

"Weill Cornell Medicine , NewYork-Presbyterian"

Sponsors
All Listed Sponsors
lead

OncoTherapy Science, Inc.

INDUSTRY

NCT02926690 - Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter